Chapter 6.3 The use of brain microdialysis in antidepressant drug research

Handbook of Behavioral Neuroscience

Volumn 16, Issue , 2006, Pages 527-543

  Artigas, Francesc ^a   Adell, Albert ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649700120     PISSN: 15697339     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-7339(06)16028-2     Document Type: Review

References (155)

1. Adell A., and Artigas F. Differential effects of clomipramine given locally or systemically on extracellular 5-HT in raphe nuclei and frontal cortex. Naunyn Schmiedebergs Arch. Pharmacol. 343 (1991) 237-244
2. Adell A., Carceller A., and Artigas F. In vivo brain dialysis study of the somatodendritic release of serotonin in the raphe nuclei of the rat. Effects of 8-hydroxy-2-(di-n-propylamino)tetralin. J. Neurochem. 60 (1993) 1673-1681
3. 2A receptors in pyramidal neurons of prefrontal cortex. Cereb. Cortex 14 (2004) 281-299
4. Andlin-Sobocki P., Jönsson B., Wittchen H.U., and Olesen J. Cost of disorders of the brain in Europe. Eur. J. Neurol. 12 Suppl. 1 (2005) 1-27
5. B receptors to the same channel in hippocampus. Science 234 (1986) 1261-1265
6. Angst J. Epidemiology of depression. Psychopharmacology 106 (1992) S71-S74
7. 1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn Schmiedebergs Arch. Pharmacol. 352 (1995) 157-165
8. 1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn Schmiedebergs Arch. Pharmacol. 353 (1996) 630-640
9. Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol. Sci. 14 (1993) 262
10. Artigas F. Selective serotonin noradrenaline reuptake inhibitors (SNRIs) - pharmacology and therapeutic potential in the treatment of depressive-disorders. CNS Drugs 4 (1995) 79-89
11. Artigas F., Celada P., Laruelle M., and Adell A. How does pindolol improve antidepressant action? Trends Pharmacol. Sci. 22 (2001) 224-228
12. Artigas F., Perez V., and Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 51 (1994) 248-251
13. 1A antagonists. Trends Neurosci. 19 (1996) 378-383
14. Auerbach S.B., Lundberg J.F., and Hjorth S. Differential inhibition of serotonin release by 5-HT and NA reuptake blockers after systemic administration. Neuropharmacology 34 (1995) 89-96
15. Ballesteros J., and Callado L.F. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J. Affect. Disord. 79 (2004) 137-147
16. Barden N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J. Psychiatry Neurosci. 29 (2004) 185-193
17. Bech P., Cialdella P., Haugh M.C., Birkett M.A., Hours A., Boissel J.P., and Tollefson G.D. Meta-analysis of randomised controlled trials of fluoxetine vs. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br. J. Psychiatry 176 (2000) 421-428
18. Béïque J.C., de Montigny C., Blier P., and Debonnel G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. In vivo electrophysiological studies in the rat. Neuropharmacology 39 (2000) 1800-1812
19. Bel N., and Artigas F. Fluvoxamine increases preferentially extracellular 5-HT in the raphe nuclei of the awake rat. An in vivo microdialysis study. Eur. J. Pharmacol. 229 (1992) 101-103
20. Bel N., and Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15 (1993) 243-245
21. Bel N., and Artigas F. Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Microdialysis studies in rats. Neuropsychopharmacology 21 (1999) 745-754
22. Benmansour S., Altamirano A.V., Jones D.J., Sanchez T.A., Gould G.G., Pardon M.C., Morilak D.A., and Frazer A. Regulation of the norepinephrine transporter by chronic administration of antidepressants. Biol. Psychiatry 55 (2004) 313-316
23. Beyer C.E., Boikess S., Luo B., and Dawson L.A. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J. Psychopharmacol. 16 (2002) 297-304
24. Blakely R.D., Berson H.E., Fremeau R.T., Caron M.G., Peek M.M., Prince H.K., and Bradley C.C. Cloning and expression of a functional serotonin transporter from rat brain. Nature 354 (1991) 66-70
25. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15 (1994) 220-226
26. Blier P., de Montigny C., and Chaput Y. Modifications of the serotonin system by antidepressant treatment: implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7 (1987) 24S-35S
27. 1A receptor knockout mice. J. Neurochem. 88 (2004) 1373-1379
28. Bosker F.J., Cremers T.I., Jongsma M.E., Westerink B.H., Wikstrom H.V., and den Boer J.A. Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: a microdialysis study in the amygdala. J. Neurochem. 76 (2001) 1645-1653
29. Bosker F.J., Klompmakers A.A., and Westenberg H.G. Effects of single and repeated oral administration of fluvoxamine on extracellular serotonin in the median raphe nucleus and dorsal hippocampus of the rat. Neuropharmacology 34 (1995) 501-508
30. 1A receptors mediate 5-hydroxytryptamine release in the amygdala through a feedback to the caudal linear raphe. Eur. J. Pharmacol. 333 (1997) 147-157
31. 1B receptors, as measured by in vivo microdialysis in dorsal hippocampus of conscious rats. Psychopharmacology 117 (1995) 358-363
32. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.L., Hemrick-Luecke S.K., and Wong D.T. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25 (2001) 871-880
33. Celada P., and Artigas F. Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat. Naunyn Schmiedebergs Arch. Pharmacol. 347 (1993) 583-590
34. Celada P., Puig M.V., Casanovas J.M., Guillazo G., and Artigas F. Control of dorsal raphe serotonergic neurons by the medial prefrontal cortex: involvement of serotonin-1A, GABA(A), and glutamate receptors. J. Neurosci. 21 (2001) 9917-9929
35. Clarke W.P., Yocca F.D., and Maayani S. Lack of 5-hydroxytryptamine(1A)-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats. J. Pharmacol. Exp. Ther. 277 (1996) 1259-1266
36. Cornwall P.L., and Scott J. Partial remission in depressive disorders. Acta Psychiatr. Scand. 95 (1997) 265-271
37. 3H]paroxetine. Neuroscience 27 (1988) 473-496
38. Cremers T.I., Giorgetti M., Bosker F.J., Hogg S., Arnt J., Mork A., Honig G., Bogeso K.P., Westerink B.H., den Boer H., Wikstrom H.V., and Tecott L.H. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 29 (2004) 1782-1789
39. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl.) 90 (1986) 131-138
40. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 18 (1990) 289-299
41. 1D autoreceptors. Neuropharmacology 35 (1996) 1627-1634
42. Daws L.C., Toney G.M., Gerhardt G.A., and Frazer A. In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters. J. Pharmacol. Exp. Ther. 286 (1998) 967-976
43. 1A receptor antagonism. Neuropharmacology 38 (1999) 1153-1163
44. de Groote L., Peñalva R.G., Flachskamm C., Reul J.M., and Linthorst A.C. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists. J. Neurochem. 94 (2005) 45-56
45. De Vivo M., and Maayani S. Characterization of the 5-hydroxytryptamine 1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea-pig and rat hippocampal membranes. J. Pharmacol. Exp. Ther. 238 (1986) 248-253
46. 1 receptor-mediated activation of hippocampal acetylcholine release in the rat and guinea-pig. Neuropeptides 37 (2003) 89-97
47. Devoto P., Flore G., Saba P., Fa M., and Gessa G.L. Stimulation of the locus coeruleus elicits noradrenaline and dopamine release in the medial prefrontal and parietal cortex. J. Neurochem. 92 (2005) 368-374
48. 1A receptors. Neurochem. Res. 21 (1996) 557-562
49. Felton T.M., Kang T.B., Hjorth S., and Auerbach S.B. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch. Pharmacol. 367 (2003) 297-305
50. Frazer A. Pharmacology of antidepressants. J. Clin. Psychopharmacol. 17 Suppl 1 (1997) 2S-18S
51. 1A) autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J. Neurosci. 21 (2001) 8188-8197
52. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115 (1995) 1064-1070
53. 1B receptors. Neuropsychopharmacology 21 (1999) 268-284
54. Gobert A., Dekeyne A., and Millan M.J. The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572. Neuropharmacology 39 (2000) 1608-1616
55. 2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J. Neurochem. 69 (1997) 2616-2619
56. 2-adrenergic receptors underlie its actions. Neuroscience 93 (1999) 1251-1262
57. 1B receptors with WAY 100,635 and GR 127,935. J. Neurochem. 68 (1997) 1159-1163
58. 1A autoreceptors in mice. J. Neurochem. 95 (2005) 1713-1723
59. Guiard B.P., Przybylski C., Guilloux J.-P., Seif I., Froger N., De Felipe C., Hunt S.P., Lanfumey L., and Gardier A.M. Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J. Neurochem. 89 (2004) 54-63
60. Gur E., Dremencov E., Lerer B., and Newman M.E. Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur. J. Pharmacol. 372 (1999) 17-24
61. Gygi S.P., Gibb J.W., Johnson M., and Hanson G.R. Blockade of tachykinin NK1 receptors by CP-96345 enhances dopamine release and the striatal dopamine effects of methamphetamine in rats. Eur. J. Pharmacol. 250 (1993) 177-180
62. Haddjeri N., and Blier P. Sustained blockade of neurokinin-1 receptors enhances serotonin neurotransmission. Biol. Psychiatry 50 (2001) 191-199
63. Hajós M., Richards C.D., Szekely A.D., and Sharp T. An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. Neuroscience 87 (1998) 95-108
64. Halliday G., Harding A., and Paxinos G. Serotonin and tachykinin systems. In: Paxinos G. (Ed). The Rat Nervous System. 2nd ed (1995), Academic Press, Sydney 929-974
65. Herpfer I., Hunt S.P., and Stanford S.C. A comparison of neurokinin 1 receptor knock-out (NK1-/-) and wildtype mice: exploratory behaviour and extracellular noradrenaline concentration in the cerebral cortex of anaesthetised subjects. Neuropharmacology 48 (2005) 706-719
66. Hervás I., and Artigas F. Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptors. Eur. J. Pharmacol. 358 (1998) 9-18
67. Hervás I., Queiroz C.M., Adell A., and Artigas F. Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br. J. Pharmacol. 130 (2000) 160-166
68. Hervás I., Vilaró M.T., Romero L., Scorza M.C., Mengod G., and Artigas F. Desensitization of 5-HT(1A) autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635. Neuropsychopharmacology 24 (2001) 11-20
69. Héry F., Faudon M., and Ternaux J.P. In vivo release of serotonin in two raphe nuclei (raphe dorsalis and magnus) of the cat. Brain. Res. Bull. 8 (1982) 123-129
70. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J. Neurochem. 60 (1993) 776-779
71. 1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur. J. Pharmacol. 260 (1994) 251-255
72. Hoffman B.J., Mezey E., and Brownstein M. Cloning of a serotonin transporter affected by antidepressants. Science 249 (1991) 1303-1306
73. 3H]imipramine, localization and relationship to serotonin transporter. J. Pharmacol. Exp. Ther. 252 (1990) 410-418
74. Hutson P.H., Sarna G.S., O'Connell M.T., and Curzon G. Hippocampal 5-HT synthesis and release in vivo is decreased by infusion of 8-OH-DPAT into the nucleus raphe dorsalis. Neurosci. Lett. 100 (1989) 276-280
75. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 9 (1994) 19-26
76. B receptor-mediated inhibition of serotonergic neurons. Eur. J. Pharmacol. 143 (1987) 195-204
77. Invernizzi R., Belli S., and Samanin R. Citalopram's ability to increase the extracellular concentration of serotonin in the dorsal raphe prevents the drug's effect in frontal cortex. Brain Res. 584 (1992) 322-324
78. 1A receptors. Eur. J. Pharmacol. 260 (1994) 243-246
79. Invernizzi R., Bramante M., and Samanin R. Extracellular concentrations of serotonin in the dorsal hippocampus after acute and chronic treatment with citalopram. Brain. Res. 696 (1995) 62-66
80. Invernizzi R., Velasco C., Bramante M., Longo A., and Samanin R. Effect of 5-HT1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology 36 (1997) 467-473
81. 2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 819-827
82. Isogawa K., Akiyoshi J., Hikichi T., Yamamoto Y., Tsutsumi T., and Nagayama H. Effect of corticotropin releasing factor receptor 1 antagonist on extracellular norepinephrine, dopamine and serotonin in hippocampus and prefrontal cortex of rats in vivo. Neuropeptides 34 (2000) 234-239
83. Kagamiishi Y., Yamamoto T., and Watanabe S. Hippocampal serotonergic system is involved in anxiety-like behavior induced by corticotropin-releasing factor. Brain Res. 991 (2003) 212-221
84. Keller M., Montgomery, Ball W., Morrison M., Snavely D., Liu G., Hargreaves R., Hietala J., Lines C., Beebe K., and Reines S. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59 (2006) 216-223
85. Kihara T., and Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J. Pharmacol. Exp. Ther. 272 (1995) 177-183
86. Kitaichi Y., Inoue T., Izumi T., Nakagawa S., Kato A., and Koyama T. Subchronic milnacipran treatment increases basal extracellular noradrenaline concentrations in the medial prefrontal cortex of rats. Eur. J. Pharmacol. 520 (2005) 37-42
87. Knobelman D.A., Hen R., and Lucki I. Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse. J. Pharmacol. Exp. Ther. 298 (2001) 1083-1091
88. Koch S., Hemrick-Luecke S.K., Thompson L.K., Evans D.C., Threlkeld P.G., Nelson D.L., Perry K.W., and Bymaster F.P. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45 (2003) 935-944
89. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., MacCoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Carlson E.J., Hardgreaves R.J., and Rupniak N.M.J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 (1998) 1640-1645
90. 1 antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study. Brain Res. 935 (2002) 134-139
91. Lepine J.P., Gastpar M., Mendlewicz J., and Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psychopharmacol. 12 (1997) 19-29
92. Lesch K.P., Wolozin B.L., Murphy D.L., and Riederer P. Primary structure of the human platelet serotonin uptake site - identity with the brain serotonin transporter. J. Neurochem. 60 (1993) 2319-2322
93. Linner L., Wiker C., Arborelius L., Schalling M., and Svensson T.H. Selective noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release in the rat forebrain. J. Neural Transm. 111 (2004) 127-139
94. 1B Autoreceptors limit the effects of selective serotonin re-uptake inhibitors in mouse hippocampus and frontal cortex. J. Neurochem. 76 (2001) 865-871
95. Malagié I., Trillat A.C., Douvier E., Anmella M.C., Dessalles M.C., Jacquot C., and Gardier A.M. Regional differences in the effect of the combined treatment of WAY 100635 and fluoxetine: an in vivo microdialysis study. Naunyn Schmiedebergs Arch. Pharmacol. 354 (1996) 785-790
96. Malagié I., Trillat A.C., Jacquot C., and Gardier A.M. Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. Eur. J. Pharmacol. 286 (1995) 213-217
97. 1 receptor antagonist. Eur. J. Pharmacol. 323 (1997) 21-26
98. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28 (2003) 402-412
99. 2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 30 (2005) 2205-2215
100. 1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus. Naunyn Schmiedebergs Arch. Pharmacol. 333 (1986) 335-341
101. 11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 24 (2001) 209-229
102. Martín-Ruiz R., Puig M.V., Celada P., Shapiro D.A., Roth B.L., Mengod G., and Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J. Neurosci. 21 (2001) 9856-9866
103. 2-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br. J. Pharmacol. 133 (2001) 1362-1370
104. 2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine. J. Neurochem. 71 (1998) 790-798
105. Mateo Y., Ruiz-Ortega J.A., Pineda J., Ugedo L., and Meana J.J. Inhibition of 5-hydroxytryptamine reuptake by the antidepressant citalopram in the locus coeruleus modulates the rat brain noradrenergic transmission in vivo. Neuropharmacology 39 (2000) 2036-2043
106. Matos F.F., Urban C., and Yocca F.D. Serotonin (5-HT) release in the dorsal raphé and ventral hippocampus: raphé control of somatodendritic and terminal 5-HT release. J. Neural Transm. 103 (1996) 173-190
107. 1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience 109 (2002) 609-617
108. Millan M.J., and Gobert A. (-)-Pindolol increases dialysate concentrations of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely-moving rats. Neuropharmacology 38 (1999) 909-912
109. Millan M.J., Gobert A., Lejeune F., Newman-Tancredi A., Rivet J.M., Auclair A., and Peglion J.-L. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther. 298 (2001) 565-580
110. 2C receptors: a comparison with citalopram. Eur. J. Neurosci. 12 (2000) 1079-1095
111. 1 receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J. Neurochem. 76 (2001) 1949-1954
112. Millan M.J., Lejeune F., and Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 14 (2000) 114-138
113. Moret C., and Briley M. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J. Neurochem. 69 (1997) 815-822
114. Murray C.J.L., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 (1997) 1498-1504
115. Nemeroff C.B. The corticotrophin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol. Psychiatry 1 (1996) 336-342
116. Nutt D.J. The neuropharmacology of serotonin and noradrenaline in depression. Int. Clin. Psychopharmacol. 17 (2002) S1-S12
117. Page M.E., and Abercrombie E.D. Discrete local application of corticotropin-releasing factor increases locus coeruleus discharge and extracellular norepinephrine in rat hippocampus. Synapse 33 (1999) 304-313
118. Palamarchouk V.S., Swiergiel A.H., and Dunn A.J. Hippocampal noradrenergic responses to CRF injected into the locus coeruleus of unanesthetized rats. Brain Res. 950 (2002) 31-38
119. 2-adrenoceptors controlling noradrenaline release in the rat dorsal hippocampus. Neuropsychopharmacology 30 (2005) 1048-1055
120. Pazos A., and Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 346 (1985) 205-230
121. Peyron C., Petit J.M., Rampon C., Jouvet M., and Luppi P.H. Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience 82 (1998) 443-468
122. Piñeyro G., and Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 51 (1999) 533-591
123. 1A receptor in the rat brain: correlation with receptor binding. J. Neurosci. 12 (1992) 440-453
124. 2C receptors. Brain Res. Mol. Brain Res. 23 (1994) 163-178
125. 3 receptors. Cereb. Cortex 14 (2004) 1365-1375
126. Quinaux N., Scuvée-Moreau J., and Dresse A. Inhibition of in vitro and ex vivo uptake of noradrenaline and 5-hydroxytryptamine by five antidepressants; correlation with reduction of spontaneous firing rate of central monoaminergic neurones. Naunyn Schmiedebergs Arch. Pharmacol. 319 (1982) 66-70
127. Raiteri M. Presynaptic autoreceptors. J. Neurochem. 78 (2001) 673-675
128. 1B serotonin receptors in adult rat brain. J. Comp. Neurol. 417 (2000) 181-194
129. Rollema H., Clarke T., Sprouse J.S., and Schulz D.W. Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J. Neurochem. 67 (1996) 2204-2207
130. 1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. J. Neurochem. 68 (1997) 2593-2603
131. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15 (1996) 349-360
132. Romero L., Celada P., and Artigas F. Reduction of in vivo striatal 5-hydroxytryptamine release by 8-OH-DPAT after inactivation of Gi/Go proteins in dorsal raphe nucleus. Eur. J. Pharmacol. 265 (1994) 103-106
133. 1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci. Lett. 219 (1996) 123-126
134. Rutter J.J., and Auerbach S.B. Acute uptake inhibition increases extracellular serotonin in the rat forebrain. J. Pharmacol. Exp. Ther. 265 (1993) 1319-1324
135. Rutter J.J., Gundlah C., and Auerbach S.B. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci. Lett. 171 (1994) 183-186
136. Sacchetti G., Bernini M., Bianchetti A., Parini S., Invernizzi R.W., and Samanin R. Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain. Br. J. Pharmacol. 128 (1999) 1332-1338
137. Sánchez C., and Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19 (1999) 467-489
138. 2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb. Cortex 14 (2004) 1100-1109
139. Santarelli L., Gobbi G., Debs P.C., Sibille E.L., Blier P., Hen R., and Heath M.J.S. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviours and increases serotonergic function. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1912-1917
140. Scuvée-Moreau J., and Dresse A. Effect of various antidepressant drugs on the spontaneous firing rate of locur coeruleus and dorsal raphe neurons of the rat. Eur. J. Pharmacol. 57 (1979) 219-225
141. Sesack S.R., Deutch A.Y., Roth R.H., and Bunney B.S. Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin. J. Comp. Neurol. 290 (1989) 213-242
142. Sotelo C., Cholley B., El Mestikawy S., Gozlan H., and Hamon M. Direct immunohistochemical evidence of the existence of 5-HT autoreceptors on serotonergic neurons in the midbrain raphe nuclei. Eur. J. Neurosci. 2 (1990) 1144-1154
143. Steinberg R., Alonso R., Rouquier L., Desvignes C., Michaud J.-C., Cudennec A., Jung M., Simiand J., Griebel G., Edmons-Alt X., Le Fur G., and Soubrié P. SSR240600 [(R)-2(1-{2-[4-{2-[3,5-bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dicholorophenyl)-2-morpholinyl]ethyl}-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 303 (2002) 1180-1188
144. Tanda G., Carboni E., Frau R., and Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?. Psychopharmacology (Berl.) 115 (1994) 285-288
145. Tanda G., Frau R., and Di Chiara G. Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology (Berl.) 127 (1996) 83-87
146. Tao R., Ma Z., and Auerbach S.B. Differential effect of local infusion of serotonin reuptake inhibitors in the raphe versus forebrain and the role of depolarization-induced release in increased extracellular serotonin. J. Pharmacol. Exp. Ther. 294 (2000) 571-579
147. Tatsumi M., Groshan K., Blakely R.D., and Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340 (1997) 249-258
148. Thase M.E., Entsuah A.R., and Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178 (2001) 234-241
149. Tollefson G.D., and Holman S.L. How long to onset of antidepressant action - a metaanalysis of patients treated with fluoxetine or placebo. Int. Clin. Psychopharmacol. 9 (1994) 245-250
150. Uhl G.R., and Hartig P.R. Transporter explosion: update on uptake. Trends Pharmacol. Sci. 13 (1992) 421-425
151. Valentini V., Frau R., and Di Chiara G. Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J. Neurochem. 88 (2004) 917-927
152. Vizi E.S., Zsilla G., Caron M.G., and Kiss J.P. Uptake and release of norepinephrine by serotonergic terminals in norepinephrine transporter knock-out mice: implications for the action of selective serotonin reuptake inhibitors. J. Neurosci. 24 (2004) 7888-7894
153. 2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J. Psychopharmacol. 18 (2004) 395-403
154. Wikell C., Hjorth S., Apelqvist G., Kullingsjo J., Lundmark J., Bergqvist P.B., and Bengtsson F. Sustained administration of the antidepressant venlafaxine in rats: pharmacokinetic and pharmacodynamic findings. Naunyn Schmiedebergs Arch. Pharmacol. 363 (2001) 448-455
155. 1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse. Neurosci. Lett. 345 (2003) 73-76